Corticosteroid Treatment in Diabetic Macular Edema
Türk Oftalmoloji Dergisi, 2017 Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial.
Burcu Nurözler Tabakcı , Nurten Ünlü
doaj +1 more source
Fluocinolone Acetonide Implant Removal From the Vitreous Cavity. [PDF]
J Vitreoretin Dis, 2023 Valikodath N, Vajzovic L.
europepmc +1 more source
Dissociation of tumor promoter-stimulated ornithine decarboxylase activity and DNA synthesis in mouse epidermis in vivo and in vitro by fluocinolone acetonide, a tumor-promotion inhibitor. [PDF]
, 1977 Ulrike Lichti +5 more
openalex +1 more source
Atrophogenic potential of fluocinolone acetonide 0.01% versus triple-combination cream and vehicle cream [PDF]
, 2005 Don Mehrabi, Amit G. Pandya
openalex +1 more source
Intravitreal Devices for the Treatment of Vitreous Inflammation
Mediators of Inflammation, 2012 The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of
John B. Christoforidis +4 more
doaj +1 more source
Sustained Release Intraocular Drug Delivery Devices for Treatment of Uveitis [PDF]
, 2011 Corticosteroids have been the mainstay of uveitis therapy. When intraocular inflammation is unresponsive to steroids, or steroid related side effects become a concern, steroid-sparing medications may be administered which can be classified into ...
Abdekhodaie, Mohammad Jafar +2 more
core +2 more sources
Stem Cells in the Hair Follicle and Interfollicular Epidermis of Mice following Topical Application of Fluocinolone Acetonide [PDF]
, 2007 Rebecca Morris
openalex +1 more source
Outcomes of Birdshot Chorioretinopathy Treated With an Intravitreal Sustained-Release Fluocinolone Acetonide–Containing Device [PDF]
, 2011 Ryan B. Rush +5 more
openalex +1 more source
Clinical Ophthalmology, 2017 Habiba Saedon,1 Astha Anand,1 Yit C Yang1,2 1Department of Ophthalmology, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, 2School of Life and Health Sciences, Aston University, Birmingham, UK Abstract: The first-line therapy for patients ...
Saedon H, Anand A, Yang YC
doaj
Indian Journal of Dermatology, 2015 Background : Melasma is a common acquired cause of facial hyperpigmentation with no definitive therapy. Tranexamic acid, a plasmin inhibitor, has demonstrated depigmenting properties and combining this oral drug with other modalities of treatment has ...
Tanmay Padhi, Swetalina Pradhan
doaj +1 more source